Insider Transactions in Q1 2025 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
5,445
-21.21%
|
$1,633,500
$300.0 P/Share
|
|
Mar 24
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
5,445
+17.5%
|
$228,690
$42.22 P/Share
|
|
Mar 24
2025
|
David E I Pyott Director |
SELL
Open market or private sale
|
Direct |
7,440
-98.2%
|
$2,224,560
$299.0 P/Share
|
|
Mar 24
2025
|
David E I Pyott Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,440
+49.55%
|
$654,720
$88.95 P/Share
|
|
Mar 21
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
4,321
-17.61%
|
$1,231,485
$285.0 P/Share
|
|
Mar 13
2025
|
Amy W Schulman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+19.73%
|
$360,250
$131.21 P/Share
|
|
Mar 04
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
808
-0.81%
|
$194,728
$241.12 P/Share
|
|
Mar 04
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
844
-1.5%
|
$203,404
$241.2 P/Share
|
|
Mar 03
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,877
-0.55%
|
$949,865
$245.33 P/Share
|
|
Mar 03
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,965
+14.91%
|
-
|
|
Mar 03
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,264
-0.37%
|
$309,680
$245.33 P/Share
|
|
Mar 03
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,117
+23.57%
|
-
|
|
Mar 03
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,749
-0.66%
|
$428,505
$245.04 P/Share
|
|
Mar 03
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
14,137
+34.28%
|
-
|
|
Mar 03
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
471
-0.28%
|
$114,924
$244.82 P/Share
|
|
Mar 03
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,137
+33.17%
|
-
|
|
Mar 03
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,911
-1.24%
|
$466,284
$244.92 P/Share
|
|
Mar 03
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,871
+19.23%
|
-
|
|
Mar 03
2025
|
Robert W. Hesslein EVP, CLO and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
757
+8.64%
|
-
|
|
Feb 28
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
496
-0.49%
|
$119,040
$240.7 P/Share
|
|
Feb 28
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
935
-0.86%
|
$224,400
$240.7 P/Share
|
|
Feb 28
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
513
-0.44%
|
$123,120
$240.7 P/Share
|
|
Feb 28
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
796
-0.29%
|
$191,040
$240.7 P/Share
|
|
Feb 28
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,900
-0.42%
|
$696,000
$240.7 P/Share
|
|
Feb 27
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+12.07%
|
-
|
|
Feb 27
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+10.09%
|
-
|
|
Feb 27
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+5.21%
|
-
|
|
Feb 27
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,921
+6.34%
|
-
|
|
Feb 18
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,548
-1.98%
|
$393,192
$254.26 P/Share
|
|
Feb 18
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,440
-2.06%
|
$365,760
$254.95 P/Share
|
|
Feb 14
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,561
-0.9%
|
$402,738
$258.13 P/Share
|
|
Feb 14
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
663
-0.38%
|
$171,054
$258.13 P/Share
|
|
Feb 14
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
967
-0.24%
|
$249,486
$258.13 P/Share
|
|
Feb 14
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,213
-0.12%
|
$312,954
$258.13 P/Share
|
|
Feb 13
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+17.08%
|
-
|
|
Feb 13
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,103
+12.31%
|
-
|
|
Feb 13
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+8.43%
|
-
|
|
Feb 13
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,859
+4.46%
|
-
|
|
Jan 27
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
52,592
-81.44%
|
$14,988,720
$285.0 P/Share
|
|
Jan 27
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
48,876
+32.77%
|
$4,301,088
$88.95 P/Share
|
|
Jan 23
2025
|
Phillip A Sharp Director |
SELL
Open market or private sale
|
Direct |
11,250
-100.0%
|
$3,093,750
$275.0 P/Share
|
|
Jan 23
2025
|
Phillip A Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+50.0%
|
$1,473,750
$131.21 P/Share
|